Therapeutic effect of TNF-alpha monoclonal antibody and TNF-alpha receptor fusion protein in children with severe infection and inflammatory storm

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044204

Enrollment

Unknown

Registered

2021-03-12

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children with severe infection

Interventions

control group:Routine treatment

experimental group:adalimumab and etanercept

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Children between 0 and 18 years old; 2. Severe pneumonia and/or sepsis. Patients were included who meet the guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019) issued by the National Health Commission of the people's Republic of China and/or who meet the International Guide to the 2020 campaign to Save sepsis: management of septic shock and sepsis-related organ dysfunction in children.

Exclusion criteria

Exclusion criteria: 1. Notifiable infectious diseases; 2. The researcher believes that he is not suitable to participate in other situations in this study; 3. Participants in other clinical trials in the same period.

Design outcomes

Primary

Measure	Time frame
general information;inflammatory factor;Infection-related indicators;Effectiveness evaluation;	—

Countries

China

Contacts

Public ContactGuoping Lu

Children's Hospital of Fudan University

13788904150@163.com+86 13788904150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026